רווח למניה בשנים עשר החודשים האחרונים: Y-mAbs Therapeutics Inc (YMAB)

Y-mAbs Therapeutics (YMAB) combines powerful scientific and technical potential in pediatric oncology radioimmunotherapy with the commercialization of precision antibodies to combat metastases. The current level of rolling earnings per share visualizes this balance, where -0.49 expresses the metric's value today. The biotech's financial stability is supported by steady revenue from the sale of Danyelza, which creates a reliable cash flow driven by niche demand.

Trailing twelve-month earnings per share (EPS TTM) reflects the portion of total income attributable to a single security, allowing investors to assess the actual return on equity without accounting for dilution. By analyzing the earnings per share over the last 12 months, one can determine how effectively Y-mAbs Therapeutics (YMAB) monetizes its orphan drug patents, despite high production costs and the logistical complexities associated with pediatric oncology.